Answers are grounded in this paper and cite their sources.
5591 Background: IO holds promise for EA with mismatch repair (MMR) or MSI-H phenotype, while trials of targeted agents matched by histology/single biomarkers have yet to meet clinical endpoints. We hypothesized a single comprehensive genomic profiling (CGP) assay could better match EA subsets to treatment modalities by simultaneously assessing MSI status, TMB, and targetable GAs. Methods: CGP of 717 FFPE EA clinical specimens by hybridization-capture of up to 315 cancer-related genes (FoundationOne) provided GA (SV, indels, CNA, rearr), TMB, and MSI status. TMB was calculated by counting mutations across a 1.25Mb region and classified as high (TMB-H; range 10.4-541 mut/Mb) or low (TMB-L; 0-10.3 mut/Mb) using the top quartile threshold. MSI high (MSI-H) or stable (MSS) status was assigned by a computational algorithm examining 114 intronic homopolymer loci. Results: Median patient age for 717 advanced or recurrent, treatment refractory EAs was 65 yrs (range 24-92 yrs). 16.9% were MSI-H, which correlated with non-serous/clear cell histology (representing 28.9% of total endometrioid, 18.8% mixed/NOS, 7.1% clear cell, and 1.5% serous cases; p < 0.0001). MMR GA (in MLH1, MSH2, MSH6, PMS2) were identified in 33% of MSI-H cases, compared to 1.9% MSS cases (p < 0.0001). Of the 173 TMB-H cases, 73% were MSI-H while 27% had a hypermutated, non-indel MSS signature (POLE GA in 16.3%). 7.4% of all MSS (43/481) samples were TMB-H and were distributed across histologies: 35% endometrioid, 40% mixed/NOS, 19% serous, 7% clear cell. GA co-occurrence frequencies differed significantly between MSI-H and TMB-H MSS EA for PTEN, MLL2, ARID1A, TP53, and KRAS (p < 0.0001). Patients with MSI-H and MSS TMB-H EA responding to IO, including 2 cases initially excluded by standard testing, will be presented. Conclusions: MSI status by CGP identified 3 times as many potentially IO-relevant cases as MMR GA, and TMB identified an additional 35% of MSS EA, including non-endometrioid subtypes. Co-occurring GA differ between TMB-L, MSI-H TMB-H, and MSS TMB-H, suggesting molecular subgroups relevant to targeted agent efficacy.
No takes yet. Share an insight, caveat, or question.
Santin et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: